-
公开(公告)号：US20110077399A1
公开(公告)日：2011-03-31
申请号：US12958237
申请日：2010-12-01
申请人： Adnan M. M. Mjalli , Robert C. Andrews , Ravindra R. Yarragunta , Rongyuan Xie , Govindan Subramanian , James C. Quada, JR. , Murty N. Arimilli , Dharma R. Polisetti
发明人： Adnan M. M. Mjalli , Robert C. Andrews , Ravindra R. Yarragunta , Rongyuan Xie , Govindan Subramanian , James C. Quada, JR. , Murty N. Arimilli , Dharma R. Polisetti
IPC分类号： C07D413/04 , C07D233/64 , C07D405/10 , C07D401/04
CPC分类号： C07D417/12 , C07D233/54 , C07D263/32 , C07D401/10 , C07D401/12 , C07D403/04 , C07D403/10 , C07D403/12 , C07D405/10 , C07D405/12 , C07D413/04
摘要： This invention provides azoles which may be useful as inhibitors of protein tyrosine phosphatases (PTPases). The present invention provides compounds of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds and their use in treating human or animal disorders. The compounds of the invention may be useful as inhibitors of protein tyrosine phosphatases and thus can be useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes, Type II diabetes.
摘要翻译： 本发明提供可用作蛋白酪氨酸磷酸酶（PTPases）的抑制剂的唑类。 本发明提供式（I）化合物，其制备方法，包含该化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物可用作蛋白酪氨酸磷酸酶的抑制剂，因此可用于由PTPase活性介导的疾病的管理，治疗，控制和辅助治疗。 这些疾病包括I型糖尿病，II型糖尿病。
-
2.发明授权Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors 有权取代的咪唑衍生物，组合物和作为PTPase抑制剂的方法公开(公告)号：US07723369B2
公开(公告)日：2010-05-25
申请号：US11699780
申请日：2007-01-30
申请人： Adnan M. M. Mjalli , Dharma R. Polisetti , Govindan Subramanian , James C. Quada , Ravindra R. Yarragunta , Robert C. Andrews , Rongyuan Xie
发明人： Adnan M. M. Mjalli , Dharma R. Polisetti , Govindan Subramanian , James C. Quada , Ravindra R. Yarragunta , Robert C. Andrews , Rongyuan Xie
IPC分类号： A61K31/4178 , C07D233/64
CPC分类号： C07D417/14 , C07D417/10
摘要： The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
摘要翻译： 本发明提供式（I-IV）的咪唑衍生物，其制备方法，包含式（I-IV）化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物抑制蛋白酪氨酸磷酸酶1B，因此可用于对由PTPase活性介导的疾病的治疗，治疗，控制或辅助治疗。 这些疾病包括I型糖尿病和II型糖尿病。
-
3.发明授权Substituted imidazole derivatives, compositions, and methods of use as PTPase inhibitors 有权取代的咪唑衍生物，组合物和作为PTPase抑制剂的方法公开(公告)号：US08404731B2
公开(公告)日：2013-03-26
申请号：US12685178
申请日：2010-01-11
申请人： Adnan M. M. Mjalli , Dharma R. Polisetti , Govindan Subramanian , James C. Quada , Ravindra R. Yarragunta , Robert C. Andrews , Rongyuan Xie
发明人： Adnan M. M. Mjalli , Dharma R. Polisetti , Govindan Subramanian , James C. Quada , Ravindra R. Yarragunta , Robert C. Andrews , Rongyuan Xie
IPC分类号： A61K31/4178 , C07D233/64
CPC分类号： C07D417/14 , C07D417/10
摘要： The present invention provides imidazole derivatives of Formula (I-IV), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I-IV), and their use in treating human or animal disorders. The compounds of the invention inhibit protein tyrosine phosphatase 1B and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases mediated by PTPase activity. Such diseases include Type I diabetes and Type II diabetes.
摘要翻译： 本发明提供式（I-IV）的咪唑衍生物，其制备方法，包含式（I-IV）化合物的药物组合物及其在治疗人或动物疾病中的用途。 本发明的化合物抑制蛋白酪氨酸磷酸酶1B，因此可用于对由PTPase活性介导的疾病的治疗，治疗，控制或辅助治疗。 这些疾病包括I型糖尿病和II型糖尿病。
-
公开(公告)号：US06933303B2
公开(公告)日：2005-08-23
申请号：US10274546
申请日：2002-10-18
IPC分类号： A61K31/437 , A61K31/573 , A61K31/64 , A61K38/28 , A61K45/00 , A61P3/00 , A61P3/04 , A61P3/08 , A61P3/10 , A61P5/10 , A61P17/06 , A61P25/28 , A61P29/00 , A61P31/00 , A61P31/04 , A61P31/18 , A61P35/00 , A61P37/04 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04
CPC分类号： C07D471/04
摘要： This invention provides compounds which are useful as inhibitors of protein tyrosine phosphatases (PTPases). As inhibitors of PTPases, the compounds of the invention are useful for the management, treatment, control and adjunct treatment of diseases mediated by PTPase activity. Such diseases include type I diabetes, type II diabetes, immune dysfunction, AIDS, autoimmunity, glucose intolerance, obesity, cancer, psoriasis, allergic diseases, infectious diseases, inflammatory diseases, diseases involving the modulated synthesis of growth hormone or the modulated synthesis of growth factors or cytokines which affect the production of growth hormone, or Alzheimer's disease.
摘要翻译： 本发明提供可用作蛋白酪氨酸磷酸酶（PTPases）抑制剂的化合物。 作为PTPase的抑制剂，本发明的化合物可用于由PTPase活性介导的疾病的治疗，治疗，控制和辅助治疗。 这些疾病包括I型糖尿病，II型糖尿病，免疫功能障碍，AIDS，自身免疫，葡萄糖不耐受，肥胖症，癌症，牛皮癣，过敏性疾病，感染性疾病，炎症性疾病，涉及调节生长激素合成的疾病或生长调节合成 影响生长激素或阿尔茨海默病生产的因子或细胞因子。
-
5.发明授权Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors 失效苯并唑衍生物，组合物和用作极光激酶抑制剂的方法公开(公告)号：US08377983B2
公开(公告)日：2013-02-19
申请号：US12703604
申请日：2010-02-10
申请人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
发明人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
IPC分类号： A01N43/38 , A01N43/52 , A61K31/405 , A61K31/497 , A61K31/535 , A61K31/415 , C07D403/00 , C07D405/00 , C07D409/00 , C07D411/00
CPC分类号： C07D417/14 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D487/04
摘要： The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
摘要翻译： 本发明涉及治疗癌症的化合物和方法。 本发明提供抑制极光激酶的化合物，包含抑制极光激酶的化合物的药物组合物，以及使用本发明化合物或包含本发明化合物的药物组合物治疗癌症的方法。
-
6.发明授权Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors 有权苯并唑衍生物，组合物和用作极光激酶抑制剂的方法公开(公告)号：US07820821B2
公开(公告)日：2010-10-26
申请号：US11704431
申请日：2007-02-09
申请人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
发明人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
IPC分类号： A61K31/496 , C07D401/14 , C07D403/14
CPC分类号： C07D417/14 , C07D401/14 , C07D403/12 , C07D403/14 , C07D409/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07D487/04
摘要： The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
摘要翻译： 本发明涉及治疗癌症的化合物和方法。 本发明提供抑制极光激酶的化合物，包含抑制极光激酶的化合物的药物组合物，以及使用本发明化合物或包含本发明化合物的药物组合物治疗癌症的方法。
-
公开(公告)号：US07820704B2
公开(公告)日：2010-10-26
申请号：US11110499
申请日：2005-04-20
申请人： Adnan M. M. Mjalli , Bapu R. Gaddam , Ghassan Qabaja , Govindan Subramanian , Jeff Zhu , John Dankwardt , Murty N. Arimilli , Robert C. Andrews , Samuel Victory , Ye E. Tian
发明人： Adnan M. M. Mjalli , Bapu R. Gaddam , Ghassan Qabaja , Govindan Subramanian , Jeff Zhu , John Dankwardt , Murty N. Arimilli , Robert C. Andrews , Samuel Victory , Ye E. Tian
IPC分类号： A61K31/427 , A61K31/381 , C07D277/38 , C07D409/12
CPC分类号： C07D277/52 , C07D239/42 , C07D277/26 , C07D277/42 , C07D277/50 , C07D277/56 , C07D277/82 , C07D403/12 , C07D405/12 , C07D409/12 , C07D417/04 , C07D417/12 , C07D417/14
摘要： The present invention provides substituted heteroaryl derivatives of Formula (I), methods of their preparation, pharmaceutical compositions comprising the compounds of Formula (I), and methods of use in treating human or animal disorders. The compounds of the invention can be useful as inhibitors of action of AgRP on a melanocortin receptor and thus can be useful for the management, treatment, control, or the adjunct treatment of diseases which may be responsive to the modulation of melanocortin receptors including obesity-related disorders.
摘要翻译： 本发明提供式（I）的取代杂芳基衍生物，其制备方法，包含式（I）化合物的药物组合物，以及用于治疗人或动物病症的方法。 本发明的化合物可用作AgRP对黑皮质素受体的作用抑制剂，因此可用于治疗，治疗，控制或辅助治疗可能对黑皮质素受体的调节（包括肥胖症 - 相关疾病。
-
公开(公告)号：US07763726B2
公开(公告)日：2010-07-27
申请号：US11704431
申请日：2007-02-09
申请人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
发明人： Adnan M. M. Mjalli , Brian S. Grella , Govindan Subramanian , Murty N. Arimilli , Ramesh Gopalaswamy , Robert C. Andrews , Stephen Davis , Xiaochuan Guo , Jeff Zhu
IPC分类号： A61K31/496 , C07D401/14 , C07D403/14
摘要： The present invention relates to compounds and methods from the treatment of cancer. The invention provides compounds that inhibit Aurora kinase, pharmaceutical compositions comprising compounds that inhibit Aurora kinase, and methods for the treatment of cancer using the compounds of the presentation invention or pharmaceutical compositions comprising compounds of the present invention.
-
公开(公告)号：US07459472B2
公开(公告)日：2008-12-02
申请号：US10913216
申请日：2004-08-06
申请人： Adnan M. M. Mjalli , Robert C. Andrews , Murty N. Arimilli , Mohan Rao , Mustafa Guzel , Muralidhar Bondlela , Xiao-Chuan Guo , Guoxiang Huang
发明人： Adnan M. M. Mjalli , Robert C. Andrews , Murty N. Arimilli , Mohan Rao , Mustafa Guzel , Muralidhar Bondlela , Xiao-Chuan Guo , Guoxiang Huang
IPC分类号： A61K31/41 , C07D271/06
CPC分类号： C07D295/155 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C271/20 , C07C311/08 , C07C311/09 , C07C311/21 , C07C311/44 , C07C317/32 , C07C323/36 , C07C2601/08
摘要： This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. Compounds of Formula (I) may be useful for treating viral infections including orthopox viruses, either alone or in combination with other therapeutic agents.
摘要翻译： 本发明提供了本文所述的式（I）的芳基和杂芳基化合物及其制备方法。 还提供了用式（I）的化合物制备的药物组合物和制备这些组合物的方法。 式（I）的化合物可用于单独或与其它治疗剂组合治疗包括正痘病毒的病毒感染。
-
公开(公告)号：US07501538B2
公开(公告)日：2009-03-10
申请号：US10913882
申请日：2004-08-06
申请人： Adnan M. M. Mjalli , Guoxiang Huang , Murty N. Arimilli , Thomas Scott Yokum , Jeff Jiqun Zhu , Muralidhar Bondlela
发明人： Adnan M. M. Mjalli , Guoxiang Huang , Murty N. Arimilli , Thomas Scott Yokum , Jeff Jiqun Zhu , Muralidhar Bondlela
IPC分类号： C07C229/00
CPC分类号： C07D295/155 , C07C233/87 , C07C235/42 , C07C235/52 , C07C235/60 , C07C235/66 , C07C237/36 , C07C237/42 , C07C271/20 , C07C311/08 , C07C311/09 , C07C311/21 , C07C311/44 , C07C317/32 , C07C323/36 , C07C2601/08
摘要： This invention provides aryl and heteroaryl compounds of Formula (I) as described herein, and methods of their preparation. Also provided are pharmaceutical compositions made with the compounds of Formula (I) and methods for making such compositions. The compounds of Formula (I) may activate an erythropoietin receptor and thus, may be useful to induce red blood cell production. The compounds of Formula (I) and compositions including compounds of Formula (I) may be useful in a variety of applications including the management, treatment and/or control of diseases caused at least in part by deficient (or inefficient) EPO production relative to hemoglobin level.
摘要翻译： 本发明提供了本文所述的式（I）的芳基和杂芳基化合物及其制备方法。 还提供了用式（I）的化合物制备的药物组合物和制备这些组合物的方法。 式（I）的化合物可以激活促红细胞生成素受体，因此可用于诱导红细胞生成。 式（I）化合物和包含式（I）化合物的组合物可用于各种应用，包括至少部分地由EPO生产缺陷（或低效）引起的疾病的管理，治疗和/或控制，相对于 血红蛋白水平。
-
-
-
-
-
-
-
-
-
搜索结果
70 条记录 (耗时 0.044 秒)
